The Life Sciences team advised eGenesis on the $191 million Series D round, led by Lux Capital and included additional investors such as Eisai Innovation, NATCO Pharma, Parkwood Corp. Arch Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, and Leaps by Bayer. The funding will help advance its lead asset, EGEN-2784, a genetically modified pig kidney.
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure. The eGenesis Genome Engineering and Production (EGEN™) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant. eGenesis has demonstrated durable preclinical success to date and is advancing development programs for kidney transplant, acute liver failure, and heart transplant.
The team was led by Catherine Magazu, Brittany Morreale, Will Ogden, Katie Lanphere, and Kingsley Taft.
For more details on the funding round, please read the press release as well as coverage in Endpoint News and Axios.